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Abstract
Background: People with schizophrenia are two to three times more likely to be overweight than the general
population. The UK National Institute of Health and Care Excellence (NICE) recommends an annual physical health
review with signposting to, or provision of, a lifestyle programme to address weight concerns and obesity. The
purpose of this randomised controlled trial is to assess whether a group-based structured education programme
can help people with schizophrenia to lose weight.
Methods: Design: a randomised controlled trial of a group-based structured education programme.
Setting: 10 UK community mental health trusts.
Participants: 396 adults with schizophrenia, schizoaffective, or first-episode psychosis who are prescribed antipsychotic
medication will be recruited. Participants will be overweight, obese or be concerned about their weight.
Intervention: participants will be randomised to either the intervention or treatment as usual (TAU). The intervention
arm will receive TAU plus four 2.5-h weekly sessions of theory-based lifestyle structured group education, with
maintenance contact every 2 weeks and ‘booster’ sessions every 3 months. All participants will receive standardised
written information about healthy eating, physical activity, alcohol and smoking.
Outcomes: the primary outcome is weight (kg) change at 1 year post randomisation. Secondary outcomes, which will
be assessed at 3 and 12 months, include: the proportion of participants who maintained or reduced their weight; waist
circumference; body mass index; objectively measured physical activity (wrist accelerometer); self-reported diet; blood
pressure; fasting plasma glucose, lipid profile and HbA1c (baseline and 1 year only); health-related quality of life (EQ-5D-
5L and RAND SF-36); (adapted) brief illness perception questionnaire; the Brief Psychiatric Rating Scale; the Client
Service Receipt Inventory; medication use; smoking status; adverse events; depression symptoms (Patient Health
Questionnaire-9); use of weight-loss programmes; and session feedback (intervention only). Outcome assessors will be
blind to trial group allocation.
Qualitative interviews with a subsample of facilitators and invention-arm participants will provide data on intervention
feasibility and acceptability. Assessment of intervention fidelity will also be performed.
Discussion: The STEPWISE trial will provide evidence for the clinical and cost-effectiveness of a tailored intervention,
which, if successful, could be implemented rapidly in the NHS.
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Background
Schizophrenia is a psychotic illness that affects approxi-
mately 1 % of the population. Mortality rates are increased
two- to four-fold in people with schizophrenia and life ex-
pectancy is reduced by 10–20 years [1–3]. Approximately
75 % of all deaths in people with schizophrenia are caused
by physical illness with cardiovascular disease being the
commonest cause of death [1]. The prevalence of type 2
diabetes is increased two-fold in people with schizophre-
nia [4]. Overweight and obesity contribute to this excess
morbidity and mortality. Recent studies indicate that
obesity is two to three times more prevalent among
people with schizophrenia than in the general population
and this occurs early in its natural history [5].
The rates of overweight and obesity have increased
substantially over the last three decades in people with
schizophrenia and to a much greater extent than in the
general population [6]. Reasons for this increase of obes-
ity are complex and relate to environmental factors, such
as poor diet and physical inactivity, as well as disease
and treatment effects. Weight gain is a common adverse
effect of antipsychotic medication, affecting between 15
and 72 % of patients [7]. Most weight gain occurs early in
treatment with between 37 and 86 % of those experiencing
a first episode of psychosis also experiencing more than
7 % weight gain in 12 months [8], often occurring within
12 weeks of treatment initiation [9]. Longer-term observa-
tional studies suggests that weight gain continues for at
least 4 years albeit at a slower rate [10].
Individuals with schizophrenia are more likely to con-
sume a diet that is rich in fat and refined carbohydrates
while containing less fibre, fruit and vegetables than that
of the general population [11–13]. Physical inactivity
and the social and urban deprivation experienced by
many people with schizophrenia may contribute further
to their increased obesity rates [12–15]. These factors
suggest that it may be possible to address the problem
of obesity through appropriate lifestyle intervention.
A meta-analysis of nonpharmacological interventions
in people with schizophrenia [16] has shown that these
led to a mean reduction in weight of 3.12 kg over a
period of 8–24 weeks. There were commensurate reduc-
tions in waist circumference and improvements in car-
diovascular risk factors. The benefits of the programmes
were seen irrespective of the duration of treatment,
whether the intervention was delivered to an individual or
in a group setting, whether the intervention was based on
cognitive behavioural therapy or a nutritional intervention
or whether it was designed to promote weight loss or pre-
vent weight gain. There was overlap across intervention
type, such that most cognitive behavioural therapy
programmes also included a diet- or exercise-based
intervention. Outpatient interventions appeared more
effective than inpatient settings.
The meta-analysis, however, acknowledges a number of
limitations of the trials, including small sample sizes and
the lack of long-term follow-up. Most previous studies do
not extend beyond 12 weeks and hence the impact of the
interventions in the longer term remains unknown. The
few studies reporting long-term effects suggest that these
may persist after the end of the programme for up to
1 year but others suggest that long-term behaviour change
is difficult to achieve [17]. The meta-analysis called for
longer trials with larger numbers, with a focus on weight
maintenance after the initial intervention.
The majority of evaluated weight-loss interventions, in-
cluding diabetes prevention programmes, have utilised in-
tensive one-to-one counselling strategies to promote
behaviour change; however, these are challenging for direct
implementation within current UK community care settings
because of resource limitations [18]. Structured education is
an alternative to one-to-one counselling and refers to group-
based, patient-centred educational programmes that have a
clear philosophy; have a written curriculum that is under-
pinned by appropriate learning and health behaviour theor-
ies; are evidence-based; and are delivered by trained, quality-
assessed, educators [19]. Structured education has been
widely advocated in England as a potentially cost-effective
method of promoting self-management and behaviour
change in individuals with chronic disease. Importantly, this
approach has recently been adopted in the promotion of life-
style change by the National Institute for Health and Care
Excellence (NICE) diabetes prevention guidance [20].
The STEPWISE intervention is based on the diabetes
prevention programme ‘Let’s Prevent Type 2 Diabetes’
[21] (often abbreviated to ‘Let’s Prevent’), which was de-
veloped by the Diabetes Education and Self-management
for Ongoing and Newly Diagnosed (DESMOND) team.
DESMOND was the first nationally established, structured
education programme and was originally designed for people
with type 2 diabetes. The programmewas effective at promot-
ing lifestyle change, including weight loss, and reducing
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symptoms of depression in a multicentred randomised con-
trolled trial (RCT) [22]. Let’s Prevent [23] is 6 h long and is de-
signed to promote increased physical activity (specifically
walking), a healthy diet through reduced fat and saturated fat
intake and increased fibre, and weight loss by enabling partici-
pants to self-regulate their behaviour actively using self-
monitoring (feedback), relapse prevention (identifying and ad-
dressing barriers to change) and goal-setting strategies.
It also includes standardised educator/facilitator train-
ing and a quality assurance programme.
Given the rapid weight gain experienced by people with
a first episode of psychosis [7], there is an urgent need to
develop interventions that lead to long-term reductions in
overweight and obesity. There is also a paucity of data in
people with first-episode psychosis and so this group is
included in the STEPWISE trial.
Aims and objectives
The aim of the STEPWISE trial is to evaluate the extent to
which a structured lifestyle education programme, when deliv-
ered to adults with schizophrenia, including those with schi-
zoaffective disorder or first-episode psychosis, in a community
mental health setting, can support weight loss at 1 year.
Having adapted the DESMOND ‘Lets Prevent’ inter-
vention for people with schizophrenia, schizoaffective
disorder or first-episode psychosis and their health care
professionals [24], the specific objectives of the trial are:
1. To undertake a multicentre RCT to test the
hypothesis that a structured self-management lifestyle
education programme can lead to a significant
increase in physical activity and improved diet leading
to clinically relevant weight loss after 1 year
2. To ensure fidelity of the intervention when scaled
up, through a robust assessment of its delivery
3. Through qualitative research, to assess whether the
intervention, when scaled up, is appropriate for and
acceptable to mental health services and people with
schizophrenia, schizoaffective disorder or first-episode
psychosis
4. To undertake an economic evaluation of the
intervention
5. To develop a quality assurance framework for
facilitators delivering the intervention
Methods
The trial is a multicentre, two-arm, parallel-group RCT of
the STEPWISE structured lifestyle education programme.
The trial design is summarised in Fig. 1. The study
was planned and implemented in concordance with the
Consolidated Standards of Reporting Trials (CONSORT)
[25]. Public and Patient Involvement was actively sought
in the development of the trial and will continue through-
out the trial.
Setting
The study will take place within community mental
health teams (CMHTs), including early intervention ser-
vices, in 10 mental health NHS trusts in the rural and
urban locations of Sheffield, Bradford, Leeds and York,
Greater Manchester, Somerset, Devon, Cornwall, Sussex,
Hampshire and South London.
Participants
Adults are eligible for inclusion in the study if they:
1. Are aged 18 years or older
2. Have a diagnosis of schizophrenia or schizoaffective
disorder (defined by International Classification of
Diseases, version 10 (ICD-10) codes F20, F25) or
first-episode psychosis (defined as less than 3 years
since presentation to the mental health team) using
case note review
3. Are being treated with antipsychotic medication; for
those with schizophrenia or schizoaffective disorder,
the treatment duration should be at least 1 month
prior to entry into the trial
4. Are able to give written informed consent
5. Are able and willing to attend and participate in a
group education programme
6. Are able to speak and read English
7. Have a Body Mass Index (BMI) ≥25 kg/m2 or are
concerned about their weight. For participants from
South Asian and Chinese backgrounds, the BMI
threshold is reduced to ≥23 kg/m2
People are excluded from the study if they have a:
1. Physical illness that could seriously reduce their life
expectancy or ability to participate in the trial
2. A coexisting physical health problem that would, in
the opinion of the principal investigator,
independently impact on metabolic measures
3. Mental illness that could seriously reduce their
ability to participate in the trial
4. Current pregnancy or are less than 6 months
postpartum
5. A condition associated with significant weight gain,
e.g. Cushing’s syndrome
6. Significant alcohol or substance misuse, which, in
the opinion of the principal investigator, would limit
the patient’s ability to participate in the trial
7. A diagnosis or tentative diagnosis of psychotic
depression or mania
8. A primary diagnosis of learning disability
People will also be excluded if they are currently (or
within the past 3 months) engaged in a systematic weight
management programme.
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Selection and randomisation
The trial will be promoted within clinical teams and
in areas where community mental health services are
delivered. Members of the research team will work
with clinical teams within the mental health trust to
identify potentially eligible patients from their case-
load. Patients can also self-refer, using information
displayed on posters or leaflets, if they are interested
in taking part.
After baseline assessments, participants will be ran-
domised using the Sheffield Clinical Trials Research
Unit’s (CTRU) remote randomisation system. A ran-
domisation list generated using permuted blocks of
random sizes will be used to allocate the participants
to either treatment as usual (TAU) plus the STEP-
WISE lifestyle education programme or TAU alone in
a 1:1 ratio, stratified by site and time since the start
of antipsychotic medication (up to 3 months or lon-
ger than 3 months). Where the exact time is un-
known, an approximate duration will be acceptable
for the purposes of randomisation.
A member of the site team will inform the partici-
pants of their allocation. Outcome assessors will be
blind to treatment allocation. Blind (or suspected)
breaks will be recorded on the Case Report Form and
reported periodically to the trial oversight committees.
Due to the nature of the intervention participants
cannot be blinded.
Assessed for eligibility by research nurse/clinical studies officer following routine clinic 
visit (or other contact) with community mental health services within each trust
Baseline data collection
Research Intervention
(n =198) 
Control (usual care) intervention
(n =198)
Randomisation (n = 396)
12 month follow-up
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health economic evaluation; intervention acceptability and implementation.
Fig. 1 Trial design
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Research intervention
Precourse information
Participants allocated to the research intervention will
be contacted by the session coordinator (administrator)
and provided with precourse information (e.g. an intro-
ductory letter and leaflet), which will confirm when the
sessions will take place and what to expect.
STEPWISE education programme
The intervention lasts for approximately 12 months.
Participants allocated to the intervention will receive
a foundation course of four weekly 2.5-h (including
breaks) group sessions delivered by two trained facili-
tators. The group sessions will involve approximately
six to eight participants, although this may vary due
to recruitment and attrition. The foundation course
will be followed by 1:1 support contact lasting about
10 min, approximately every 2 weeks for the remain-
der of the intervention period, from a facilitator in
order to support behaviour change. Ideally, support
contact will be personalised and carried out face-to-
face or by telephone. Participants will be invited to
attend group-based booster education sessions at 4, 7
and 10 months post randomisation. Group attendance
and receipt of support contact will be recorded.
Intervention sessions include: individual personal stories;
taking control of weight; healthier food and drink choices;
the relationship between weight and medication; and the
relationship between calories and portions and physical ac-
tivity (see Additional file 1). The intervention has a written
curriculum to ensure consistency and resources that are in
line with meeting its person-centred philosophy. Partici-
pants will not be ‘taught’ in a formal way, but rather sup-
ported to discover and work out knowledge for themselves,
and to allow this to inform their goals and plans.
Participants attending education sessions will be invited
by facilitators to complete a ‘Session Feedback’ form at the
end of each session. The aim is to capture a self-report of
empowerment and health belief during the course; the fa-
cilitators will not read the forms. Participants are not en-
couraged to bring someone with them to the intervention
sessions; however, if they do, this will be documented.
Facilitator training
At least four health care professionals or associated staff
at each location will receive facilitator training to deliver
the STEPWISE education programme. Training com-
prises: the core DESMOND philosophy (1 day); and,
specific content and delivery of the STEPWISE
programme including content and delivery of booster
sessions and support contact (3 days). Training will be
preceded by a set of preparation exercises. Training will
follow the philosophy and psychological principles that
underpin patient education initiatives.
Control arm
Participants in the control arm will receive TAU. There
is significant variability in the provision of physical
health care, despite the NICE guidelines on treatment
and management of schizophrenia regarding healthy eat-
ing and physical health [26].
In order to standardise usual care in both groups, as
far as possible, centres will provide printed advice to all
participants at baseline (prior to randomisation) on the
risk of weight gain and lifestyle advice, including infor-
mation about diet and physical activity, and smoking
and alcohol use (as appropriate). We will record any up-
take of weight management and/or physical activity pro-
grammes by all participants during the study, and collate
information from centres about uptake of NICE recom-
mendations more widely.
Outcome measures
Consistent with the primary objective of this trial, the
primary endpoint is change in weight (kg) at 12 months
after randomisation.
Secondary outcomes include: proportion of participants
who maintained or reduced their weight, waist circumfer-
ence, body mass index, physical activity captured via wrist
accelerometer, blood pressure, fasting plasma glucose,
lipid profile and HbA1c; behaviour change (self-reported
diet; smoking status) and psychosocial factors including
quality of life (RAND SF-36 [27]and EQ-5D-5L [28]);
health beliefs (adapted Brief Illness Perception Question-
naire [29]; Brief Psychiatric Rating Scale [30]) and
cost-effectiveness (Client Service Receipt Inventory [31]).
Secondary outcomes also include: medication use; adverse
events; depression symptoms (Patient Health
Questionnaire-9 [32]); use of weight-loss programmes;
and session feedback (intervention participants only). All
outcome measures will be assessed at baseline and after 3
and 12 months (except where stated) to measure if there
is an effect and, if so, whether this is sustained in the lon-
ger term. Follow-up windows for 3- and 12-month follow-
ups will be defined as minus 2 weeks and plus 4 weeks to
allow time for missed appointments. A schedule of enrol-
ment, interventions, and assessments based on the SPIRIT
2013 Figure [33] is shown in Fig. 2.
The research nurse or clinical studies officer will ad-
minister all questionnaires and other assessments either
at the participant’s home or in the NHS trust. Additional
information (e.g. medication) may be obtained from the
patient’s notes. All participants will receive a £20 voucher
at the 12-month assessment.
The operational criteria OPCRIT Checklist for psych-
otic and affective illness will be completed from case
note review within 10 weeks post baseline visit to pro-
vide baseline characteristics. Collection of fasting blood
sample and accelerometer data will be permitted after
Gossage-Worrall et al. Trials  (2016) 17:475 Page 5 of 12
randomisation where recruitment is close to the sched-
uled education course.
Safety assessments
There are few anticipated adverse effects of this struc-
tured lifestyle intervention. The development of the
intervention ensured that it was tailored to the needs of
people with schizophrenia, schizoaffective disorder and
first-episode psychosis. There is a risk that anxiety about
weight and its complications may be increased. If the
intervention is unsuccessful this may lead to feelings of
poor self-esteem. These risks probably are outweighed
by the risk of widening health inequality and worsening
health among people with schizophrenia if the interven-
tion is not assessed.
The following are expected serious adverse events for
the patient population:
1. Psychiatric hospitalisation
2. Self-harm
3. Suicide attempt
4. Death from suicide
Adverse events will be monitored at 3- and 12-month
follow-ups. All serious adverse events that are also both
‘unexpected’ (that is, the type of event is not listed in the
STUDY PERIOD
Enrolment Allocation Post-allocation - Intervention delivery and research follow-up
TIMEPOINT
(m = month)
10 Mar 2015 
– 31 Mar 
2016
0 m 1m – 2m 3 m 4 m 7 m 10 m 12 m
ENROLMENT:
Eligibility screen X
Informed consent X
Written lifestyle information X
Allocation X
INTERVENTIONS:
Usual care plus structured education
Usual care
ASSESSMENTS:
Medical history X
Psychiatric history X
Operational Criteria Checklist for 
Psychotic Illness and Affective Illness
X
Renal function X
Hepatic function X
Height (to calculate body mass index) X
Weight X X X
Waist circumference X X X
Physical activity (wrist worn 
GENEActiv accelerometer up to 7 
days)
X X X
Adapted Dietary Instrument for 
Nutrition Education questionnaire
X X X
Blood Pressure X X X
Fasting glucose X X
Lipid profile X X
Glycated haemoglobin X X
EQ-5D-5L X X X
RAND Short Form 36 X X X
Brief Illness Perception Questionnaire X X X
Brief Psychiatric Rating Scale X X X
Smoking status X X X
Client Service Receipt Inventory X X X
(Changes in) medication (dose and 
side effects)
X X X
Patient Health Questionnaire 9 X X X
Use of weight loss programmes X X
Adverse events X X
Session feedback X X X X
Fig. 2 SPIRIT Figure – Schedule of enrolment, interventions, and assessments, based on recommendations for Interventional Trials (SPIRIT) figure,
for the STEPWISE trial. Following enrolment, all participants receive written lifestyle information; and, before collection of 0 month assessments.
Participants are then randomised to either usual care with structured education or usual care. Participants allocated to structured education are
invited to: a) 4 weekly 2.5 hour group sessions (delivered by trained facilitators); group booster sessions at 4, 7 and 10 months post-
randomisation; and, 1:1 support contact between month 2 and month 12. Research assessments are completed with all participants at 0, 3 and
12 months (as indicated)
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protocol as an expected occurrence); and ‘related’ (that
is, it resulted from administration of any of the research
procedures) will be reported by sites to the central team
and the sponsor for expedited reporting to the trial over-
sight committees and the Research Ethics Committee.
Sample size
The sample size calculation is based on data obtained from
two sources, both of which evaluated behavioural interven-
tions for weight loss in people prescribed antipsychotic
medication for schizophrenia. Das et al. undertook a
systematic review of randomised and nonrandomised
controlled trials which reported between-group differ-
ences of 1.5 to 6 kg with standard deviations of around
5 kg [34]. The second source was data on overweight and
obese UK patients with severe mental illness in which 51
people with schizophrenia were followed up for at least
1 year; among these, the weight change was 7.7 kg with a
standard deviation of 6.5 kg [35]. We propose to detect a
difference of 4.5 kg, which is both clinically meaningful
(being on average around a 5 % reduction in body weight)
[36] and appears compatible based on previous work. As-
suming a conservative estimate of the standard deviation
(SD) of 10 kg, 95 % study power, and two-sided signifi-
cance level of 5 %, 130 participants per arm (260 in total)
are required in order to detect a minimum clinically im-
portant difference of 4.5 kg.
Since the intervention is delivered in groups, the out-
comes of the participants within the same group may be
correlated. Assuming on average of seven participants
per group, and an intraclass correlation of 5 % in the
intervention arm, the sample size will be inflated by a
design effect of 1.3 in the intervention arm in order to
allow for this, which yields revised sample sizes of 169
and 130 in the intervention and control arms, respect-
ively (299 in total). To maintain a 1:1 allocation, 158 par-
ticipants per arm are required to reproduce this power.
We further anticipate a conservative dropout rate of
around 20 % (higher than that observed in similar stud-
ies [37], giving a final total of 198 participants per arm.
With 10 centres, this requires 40–50 participants per
centre (rounded upwards), 20–25 of whom will receive
the intervention in three to four groups.
Internal pilot
The trial includes an internal pilot which will assess
whether it is feasible to recruit and retain sufficient par-
ticipants. By 11 September 2015, the middle of the pro-
ject (month 24):
1. Ten centres should have been initiated and should
have recruited their first participant
2. Two hundred and fifty participants should have
been recruited
3. Six centres should have completed their first
STEPWISE course
4. Ninety-six participants should have been followed
up to their 3-month outcome assessment
The trial will be considered infeasible and will be stopped
if one or more of the following conditions apply:
1. Fewer than six centres have recruited their first
participant
2. Fewer than 125 participants have been consented
3. Fewer than three centres have completed their first
4-week STEPWISE course
4. Fewer than 75 % of those followed up to their 3-
month outcome assessment have contributed valid
weight (primary outcome at 12 months) data at this
time point
Data analysis
Data will be analysed and reported according to the guide-
lines of the revised CONSORT statement for randomised
controlled trials [25].
The analysis will be performed on an intention-to-treat
basis and all statistical tests will be two-tailed at 5 % sig-
nificance level. Demographics and baseline characteristics
will be summarised and assessed for comparability be-
tween the intervention and control arms [38, 39].
The primary outcome will be assessed by fitting a mar-
ginal generalised estimating equation model (GEE) ad-
justed for baseline weight, using robust standard errors
and an exchangeable correlation structure. This model
incorporates an adjustment for potential clustering or
correlation among the outcomes of participants treated in
the same group. A 95 % confidence interval for the differ-
ence in weight between the lifestyle intervention and con-
trol arms will be reported with its associated P value. A
sensitivity analysis will be performed in the same manner,
which will include baseline covariates and any observed
imbalances. In case of missing data, the missing data
mechanism will be explored and multiple imputation ap-
proach applied to assess the robustness of the findings.
Of key interest is whether the intervention conveys
the same effect among recently diagnosed patients
(i.e. patients experiencing first-episode psychosis) as it
does among those established on antipsychotic medi-
cation for a greater period of time. We will investi-
gate this in the analysis by fitting an interaction term
between treatment group and the time since starting
antipsychotic medicine (including a nonlinear term if
appropriate). The treatment effect will be presented
graphically for different subgroups of the time elapsed
since commencing medication.
Other continuous outcomes will be analysed and re-
ported in the same manner as the primary outcome.
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Analysis of binary outcomes will be undertaken using a
marginal generalised logistic linear regression model
within the GEE framework and difference between treat-
ment groups will be reported as odds ratios with associ-
ated 95 % confidence intervals and P values.
Economic evaluation
The economic evaluation will be from a health and social
care and societal perspective. The number of intervention
sessions received will be centrally recorded. The cost of
the intervention will be based on staff time plus overheads
(capital and administrative) and an element for training
and supervision. Other service use will be recorded at
baseline and at 3- and 12-month follow-ups using the
interviewer-administered Client Service Receipt Inventory,
and will include:
 primary care
 secondary care, including inpatient costs
(specialist mental health and physical health services)
 social care
 psychotropic and other medication, and
 informal care from families or friends (expressed in
terms of hours per week spent on specific tasks
because of the participant’s health problems)
Service costs will be calculated by combining the above
data with appropriate unit cost information [40, 41]. Infor-
mal care time will be valued using average wage rates with
sensitivity analyses using minimum wage rates and the
value of a homecare worker. Lost work time will also be
recorded for those in employment and valued using aver-
age wage rates. Total health and social care costs and soci-
etal (i.e. including informal care and lost employment)
costs will be reported and compared between the two
groups for the 1-year follow-up. A regression model will
be used with baseline costs controlled for and boot-
strapped 95 % confidence intervals generated given the ex-
pected skewed cost distribution.
Cost-effectiveness will be assessed by combining the
cost data (from both perspectives) with the primary out-
come measure and QALYs. The latter will be generated
from the EuroQol five dimensions, five levels question-
naire (EQ-5D-5L) using UK tariffs and area under the
curve methods. If the intervention results in lower
(higher) costs and better (worse) outcomes then it will be
dominant (dominated). In the event of higher costs and
better outcomes (or lower costs and worse outcomes),
incremental cost-effectiveness ratios (ICERs) will be
constructed to show the cost per extra unit of weight loss
or extra QALY gained. Uncertainty around the ICERs will
be addressed by constructing cost-effectiveness planes
using 1000 bootstrapped cost-outcome pairs and cost-
effectiveness acceptability curves (CEACs). The latter will
indicate the probability that the intervention is more cost-
effective than TAU for different threshold values placed
on a unit reduction in weight or one more QALY gained.
The NICE uses a threshold of £20,000–30,000 for a QALY
gain and so the CEACs will include this value in the range
of values. There are no recognised threshold values of a
unit reduction in weight and so values will be reported at
which the intervention or TAU has a 50 %, 70 %, 80 %
and 90 % likelihood of being the most cost-effective
option.
Sensitivity analyses will be conducted by varying the
costs of the intervention, informal care and lost employ-
ment. QALYs based on the SF6D (derived from the
RAND Short Form 36-item Health Survey; SF-36) will
also be used in sensitivity analyses given that this argu-
ably has better distributional properties than EQ-5D-5L-
based QALYs in this patient population [42]. The EQ-
5D-5L has a clear ceiling effect in people with schizo-
phrenia while the SF6D is normally distributed.
Process evaluation
A process evaluation will be undertaken ‘to explain dis-
crepancies between expected and observed outcomes, to
understand how context influences outcomes, and to
provide insights to aid implementation’ [43]. We will use
a modified version of Linnan and Steckler’s framework
for process evaluation [44]. The context for intervention
implementation will be explored using qualitative in-
terviews, schedules for which will be developed by a
multidisciplinary team including potential participants
and will investigate whether the intervention, when
scaled up, is appropriate for and acceptable to mental
health services (i.e. facilitators) and service users. We
will explore other aspects (e.g. reach, dose delivered
and received) quantitatively.
The methods of recruitment will also be explored
both qualitatively and quantitatively. We will not produce
a composite score for implementation as proposed by
Linnan and Steckler, as we do not believe such a score
would have validity or utility for our intended audience.
Qualitative component of STEPWISE trial
Participant interviews
Approximately 20–24 participants will be purposively
sampled, from those consenting to be contacted about
the qualitative interview, to recruit different genders
and ages.
All interviews will be via telephone or face-to-face and
last about 1 h depending on the participant’s response and
wishes. Interviews will not be conducted until after the 3-
month follow-up visit. The qualitative research will also
inform the quantitative aspects of the process evaluation.
A semistructured interview topic guide, will contain
general open questions exploring the experience and
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acceptability of the intervention to participants. It will
also include questions intended to elicit themes outlined
in the existing published literature such as the barriers
to, and facilitators of, the use of lifestyle interventions in
people with schizophrenia [45–47].
Facilitators interviews
The process evaluation will explore health care pro-
fessionals’ views on the experience of incorporating
the lifestyle intervention into practice through indi-
vidual semistructured interviews with approximately
20 facilitators.
May’s ‘Normalisation Process Theory’ (NPT) will be
used as a theoretical framework to understand better the
conditions necessary to support the introduction, embed-
ding and integration of protocolised lifestyle interventions
as routine elements of care [48]. While NPT emphasises
the influence of social systems on behaviour, the study
will also utilise relevant domains from the Theoretical
Domains Framework (TDF) [49, 50] which emphasises
individual influences on behaviour. We will also collect
facilitator characteristics (e.g. level of education). The
process evaluation will inform the interpretation of the
trial results and subsequent policy-making, in line with
the MRC’s Complex Intervention Framework [43].
All semistructured interviews will be audio-taped and
fully transcribed using the National Centre for Social
Research ‘Framework’ approach [51].
Facilitator training and assessment of intervention fidelity
A fidelity assessment will be undertaken to investigate
whether the intervention can be delivered faithfully
when scaled up. As the facilitators’ delivery of the inter-
vention is key, an assessment of facilitator performance
in each of the participating centres will be conducted
during the RCT.
The facilitator training programme and intervention
fidelity checks will be undertaken through the DESMOND
collaborative and based on the standardised and estab-
lished criteria currently used to provide quality assurance
in the DESMOND National Programme.
During the trial, the delivery of individual facilitators
at each centre will be assessed against criteria derived
directly from the STEPWISE programme. This will en-
able the study team to identify if there is any deviation
from the delivery taught in training, and will also pro-
vide evidence for establishing a benchmark for delivery
and facilitator competencies when the intervention is
scaled up. All training and assessment procedures will
be supportive and transparent.
Although it is not possible to identify the final suite of
intervention fidelity tools, these are likely to include as-
sessment of content delivery; assessment of facilitator
behaviour against a set of criteria derived from the
STEPWISE programme itself; and assessment of facilita-
tor talk time, using the DESMOND Observational Tool
(DOT). The latter assessment involves an independent
assessor scoring activity in the session (e.g. who is speak-
ing; miscellaneous activity) through use of a 10-s audio
prompt (audible only to the assessor). It has been shown
that the amount of time facilitators or participants spend
speaking is predictive of the changes observed in the
participants’ illness perceptions: less facilitator talk leads
to a greater change in participants’ beliefs about their
condition [36] and is a precursor to behaviour change.
Intervention fidelity assessments will be used to inform
the outcomes of the trial.
Trial supervision
Sheffield Health and Social Care NHS Foundation Trust
will act as the sponsor for the trial and, therefore, will have
overall responsibility for the trial along with the chief
investigator. Trial management will be provided by the
Sheffield Clinical Trials Research Unit (CTRU), which
adheres to its Standard Operating Procedures. The
study will use the CTRU’s in-house, access-controlled,
data management system for the capture and storage of
participant data. Level and frequency of monitoring has
been agreed with the sponsor. Three committees will
govern the conduct of this study: the Trial Steering Com-
mittee (TSC); the Data Monitoring and Ethics Committee
(DMEC); and the Trial Management Group (TMG). The
TMG will oversee the day-to-day management of the trial.
The DMEC is the only group with access to the unblinded
outcome date while the trial is underway.
Discussion
Several previous RCTs [16, 17] and long-term observa-
tional studies [35] have shown that lifestyle interventions
are effective among people with schizophrenia. However,
the current RCT data are limited because of the small
numbers of participants involved and their short dur-
ation. In addition, few studies have included people with
a first episode of psychosis and yet weight gain occurs
commonly and rapidly in this group of individuals after
treatment initiation. This trial will address these limita-
tions by recruiting a large number of participants who
will be followed for a year. We have also specifically in-
cluded people with first-episode psychosis, where the
aim of the intervention may be the prevention of weight
gain rather than weight loss.
The importance of managing obesity and overweight
in people with schizophrenia is recognised in a number
of national and international guidelines. These advocate
regular assessment of weight and the implementation of
lifestyle modification to address weight gain. Despite the
NICE guidance that recommends provision of a com-
bined healthy eating and physical activity programme by
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mental health care providers, there is uncertainty about
how to implement this, reflected by the large variation
in the provision of care between different NHS trusts.
This trial is being undertaken in 10 mental health trusts
from differing geographical areas in England, serving dif-
ferent populations, to maximise generalisability of the
findings. If this trial shows the STEPWISE intervention
to be effective, the diversity of centres in the study
should aid the implementation of the intervention more
widely across the NHS.
The intervention is based on the existing Let’s Prevent
programme of the DESMOND collaborative. The DES-
MOND programme is approved by the NICE for people
with, or at risk of, type 2 diabetes. It has a well-established
training and evaluation process, which could be extrapo-
lated to mental health care professionals wishing to imple-
ment STEPWISE.
Although lifestyle programmes have been introduced
in some mental health settings, no research has been
performed to determine the acceptability of these pro-
grammes. People with severe mental illness have similar
levels of interest in their cardiovascular health as the
general population but are not always able to prioritise
their physical health [52]. It is important to assess the
acceptability of lifestyle programmes for patients and
mental health care professionals. This trial will provide
information about this issue.
Treating obesity with either lifestyle or pharmacological
interventions is cost-effective in the general population but
it is important to evaluate whether this is true for people
with schizophrenia. The DESMOND programme has been
shown to be cost-effective; using 2010 real-world costs of
the intervention, the lifetime incremental cost was £82 and
mean incremental cost per QALY was £2113 [53].
By 11 September 2015 the trial had met (and in some
instances substantially exceeded) feasibility criteria in-
cluded in the internal pilot which included the number
of recruiting sites, the number of recruited participants,
the delivery of the first STEPWISE intervention and
rates of retention at 3 months.
Protocol changes
The trial is largely being conducted as it was originally
envisaged. Prior to starting the trial, the method of cal-
culating the primary outcome (weight) was altered
from absolute weight to change in weight (kg) follow-
ing advice received from the first TSC meeting. A
small number of other modifications have been made,
some of which were a result of the Intervention Devel-
opment Study whilst others relate to the group-based
intervention (e.g. sites were encouraged to recruit in
waves not too far ahead of a scheduled course).
In conclusion, the STEPWISE trial will provide evi-
dence for the clinical and cost-effectiveness of a group-
based structured education programme designed to help
people with schizophrenia, schizoaffective disorder or
first-episode psychosis to lose weight or attenuate weight
gain. If the intervention is successful, the design of the
intervention and trial will allow a rapid dissemination
within the NHS.
Trial status
Participant recruitment finished on 31 March 2016 (n =
414 recruited) and the trial is in follow-up.
Additional file
Additional file 1: Table S1. STEPWISE foundation and booster session
curriculum. (PDF 9 kb)
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